NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1270.30 -21.80 (-1.69%)

2.0M NSE+BSE Volume

NSE 31 Jul, 2025 3:31 PM (IST)

106,016.9

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

27 Feb 2017

1270.30

-1.69%

Company Update:Dr Reddys Labs

Sell: Dr. Reddy's Laboratories Ltd.

Axis Direct

US District Court has ruled that Dr Reddy's (DRRD) NDA (505 (b)(2))for Aloxi (Palonosetron) infringes 3 outstanding patents and also turned down its claim's to invalidate 2 patents.

Deven Choksey released a Sell report for Dr. Reddy's Laboratories Ltd. with a price target of 1120.0 on 29 Jul, 2025.

Dr. Reddy's Laboratories Ltd.

22 Feb 2017

1270.30

-1.69%

Result Updates

Neutral: Dr. Reddy's Laboratories Ltd.

Angel Broking

Dr. Reddy's Laboratories (DRL) posted lower than expected results for 3QFY2017. In INR terms, the consolidated revenues came in at Rs3,707cr (v/s. Rs4,000cr expected) v/s. Rs3,989cr in 3QFY2016, down 6.6% yoy, mainly driven by pressure on the generic market. The global generic market with sales at Rs3,064cr (down 9.0% yoy), was mainly lea..

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1282.9

Dr. Reddy's Laboratories Ltd.

10 Feb 2017

1270.30

-1.69%

Result Update:Dr Reddys Labs

Sell: Dr. Reddy's Laboratories Ltd.

Axis Direct

While Dr Reddy's (DRRD) Q3 positively surprised us with expansion in gross margin (+300bps QoQ on better revenue mix), guidance of relatively softer Q4 on(1) delay in launch/ approval of key products (gAloxi, gGleevec) in US and (2) manufacturing issues in one of its key product was disapp..

Dr. Reddy's Laboratories Ltd.'s price crossed below 50Day SMA today

Dr. Reddy's Laboratories Ltd.

08 Feb 2017

1270.30

-1.69%

EARNINGS UPDATE - DR REDDY LAB

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Chola Wealth Direct

Background: Dr. Reddy's is a global generic pharmaceutical company with focus on the US, Europe, Russia and India. Finished dosage and API account for a bulk of the revenues, with up to 60% of sales derived from overseas operations. With a strong research pipeline, its R&D; is focused in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infections. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. It has one of the largest ANDA & a patent challenge pipeline has strengthened presence through the launch of several...

Dr. Reddy's Laboratories Ltd.'s price crossed below 50Day SMA today

Dr. Reddy's Laboratories Ltd.

07 Feb 2017

1270.30

-1.69%

Dr Reddy's Laboratories

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 6.6% YoY to | 3707 crore (I-direct estimate: | 3659 crore) mainly due to 15% decline in US sales to | 1660 crore (I-direct estimate: | 1681 crore). The Indian formulations business grew a mere 2% to | 595 crore (I-direct estimate: | 604 crore) EBITDA margins declined 258 bps to 23.5% (I-direct estimate: 18.0%) but increased 594 bps QoQ mainly due to a sharp improvement in gross margins as well as lower SG&A; and R&D; spend...

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

06 Feb 2017

1270.30

-1.69%

Dr Reddys Laboratories Ltd Q3FY17 results comment

Results Update: Dr. Reddy's Laboratories Ltd.

HDFC Securities

Revenue rose by 3.37% to Rs. 3706.5 Cr in Q3FY17 when compared to the previous quarter. On the other hand, it fell by 6.59% when compared with Q3FY16.

Dr. Reddy's Laboratories Ltd.'s price crossed below 50Day SMA today

Is Dr. Reddy's Laboratories Ltd. worth buying?

518 Votes:

Buy 78.38%

Sell 11.97%

Hold 9.65%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf